-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Upgrades Arrowhead Pharma to Overweight, Raises Price Target to $100

Benzinga·04/21/2026 11:12:19
Listen to the news
Morgan Stanley analyst Michael Ulz upgrades Arrowhead Pharma (NASDAQ:ARWR) from Equal-Weight to Overweight and raises the price target from $78 to $100.